文献速递产科母胎医学

阿司匹林预防双胎妊娠子痫前期及不良围产结局:系统综述与Meta分析

Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
PubMed 文献 · Am J Obstet Gynecol MFM · 2022-11-17

该系统综述与Meta分析纳入9项研究共2273例双胎妊娠,评估阿司匹林对子痫前期及不良母胎结局的作用。汇总分析显示阿司匹林组子痫前期风险低于未用药组(OR 0.64,95%CI 0.48-0.85,P=.003),仅限阿司匹林剂量>100 mg/d的研究中子痫前期风险亦显著降低(OR 0.45,95%CI 0.23-0.86,P=.02)。妊娠期高血压、胎儿生长受限、不良母胎事件、分娩孕周及新生儿出生体重组间均无显著差异。

要点

  • 双胎妊娠使用阿司匹林者子痫前期风险低于未使用者(OR 0.64,95%CI 0.48-0.85)。
  • 仅纳入阿司匹林剂量>100 mg/d的研究时,子痫前期风险显著降低(OR 0.45,95%CI 0.23-0.86)。
  • 妊娠期高血压、胎儿生长受限及不良母胎事件风险组间无显著差异。

核心结论

  • 双胎妊娠女性使用阿司匹林可降低子痫前期风险。
  • 作者认为需要随机对照试验来阐明阿司匹林对双胎妊娠母胎结局的实际作用。

研究设计与样本

  • 系统综述与Meta分析,检索Medline、Embase、Google Scholar、Cochrane及ClinicalTrial.gov数据库,检索与筛选限于英文文献。
  • 共纳入9项研究、2273例双胎妊娠。
  • 采用Cochrane修订版随机试验偏倚风险评估工具由2名研究者独立进行质量评价,并用GRADE评估主要结局的证据质量。

主要发现

  • 汇总所有研究,阿司匹林组子痫前期风险低于未用药组(OR 0.64,95%CI 0.48-0.85,P=.003)。
  • 妊娠期高血压(P=.987)、胎儿生长受限(P=.9)、不良母胎事件(P=.9)、分娩孕周(P=.2)及新生儿出生体重(P=.06)在用药组与未用药组间均无显著差异。
  • 仅纳入阿司匹林剂量>100 mg/d的研究时,子痫前期风险显著降低(OR 0.45,95%CI 0.23-0.86,P=.02),而妊娠期高血压(P=.20)、胎儿生长受限(P=.1)、分娩孕周(P=.06)及新生儿体重(P=.05)组间无显著差异。
  • 仅纳入阿司匹林剂量>80 mg/d的研究时,子痫前期风险组间无显著差异(P=.611)。
  • 阿司匹林与子痫前期的关联在阿司匹林剂量>100 mg/d或于孕16周前开始用药时持续存在。

关键数值与推荐

  • 主要结局为子痫前期发生率;次要结局包括妊娠期高血压、胎儿生长受限、孕34周前早产(自发性或医源性)、分娩孕周、新生儿出生体重及阿司匹林相关不良事件(产前和产后出血)。
  • 按绒毛膜性(双绒毛膜 vs 单绒毛膜)、阿司匹林剂量、给药孕周(<16周 vs ≥16周)进行亚组分析,并单独分析每日阿司匹林剂量≥100 mg/d的研究。
  • 采用报告汇总比值比和均数差的头对头Meta分析分别分析分类变量和连续变量。
  • GRADE评估的总体证据质量为低。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • GRADE评估的总体证据质量为低。
  • 作者认为需要随机对照试验来阐明阿司匹林对双胎妊娠母胎结局的实际作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aimed to investigate the potential role of aspirin in reducing the risk of preeclampsia and adverse maternal and perinatal outcomes in twin pregnancies. DATA SOURCES: Medline, Embase, Google Scholar, Cochrane, and ClinicalTrial.gov databases were searched. STUDY ELIGIBILITY CRITERIA: The search and selection criteria were restricted to the English language. METHODS: The primary outcome was the incidence of preeclampsia. The secondary outcomes included gestational hypertension; fetal growth restriction; preterm birth, either spontaneous or iatrogenic, before 34 weeks of gestation; gestational age at birth; neonatal birthweight; and adverse events secondary to the administration of aspirin, including antepartum and postpartum hemorrhage. In addition, subgroup analyses according to chorionicity (dichorionic vs monochorionic), aspirin dose, and gestational age at administration of aspirin (<16 vs ≥16 weeks of gestation) and considering only studies with a daily aspirin dose of ≥100 mg/d were performed. Head-to-head meta-analyses reporting results as summary odds ratios and mean differences were used to analyze categorical and continuous variables, respectively. Quality assessment for randomized controlled trials was independently performed by 2 researchers based on the risk of bias that was assessed using the revised Cochrane risk-of-bias tool for randomized trials. The conclusion of the meta-analysis on the primary outcome was assessed using the Grading of Recommendations, Assessment, Development, and Evaluation. RESULTS: Overall, 9 studies (2273 twin pregnancies) were included. When considering all studies, the risk of preeclampsia was lower in twin pregnancies treated with aspirin than in those not treated with aspirin (odds ratio, 0.64; 95% confidence interval, 0.48-0.85; P=.003), although there was no significant difference in the risk of gestational hypertension (P=.987), fetal growth restriction (P=.9), or adverse maternal and perinatal events (P=.9) in twin pregnancies treated with aspirin compared with those not treated with aspirin. There was no significant difference in the gestational age at birth (P=.2) and neonatal birthweight (P=.06) between women receiving aspirin and those not receiving aspirin. When considering only studies with an aspirin dose of >100 mg/d, the risk of preeclampsia (odds ratio, 0.45; 95% confidence interval, 0.23-0.86; P=.02) was significantly lower in pregnancies receiving aspirin than in those not receiving aspirin, Conversely, there was no significant difference in the risk of gestational hypertension (P=.20), fetal growth restriction (P=.1), gestational age at birth (P=.06), and neonatal weight (P=.05) between the 2 groups. Furthermore, there was no significant difference in the risk of preeclampsia when considering only studies with an aspirin dose of >80 mg/d (P=.611). The association between the administration of aspirin and preeclampsia persisted when considering an aspirin dose of >100 mg/day or when the medication was started before 16 weeks of gestation. The overall quality of evidence using the Grading of Recommendations, Assessment, Development, and Evaluation assessment was low. CONCLUSION: The administration of aspirin in women with twin pregnancies reduced the risk of preeclampsia. The findings from this study highlighted the need for randomized controlled trials elucidating the actual role of aspirin in affecting maternal and perinatal outcomes in twin pregnancies.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. D'Antonio F, Khalil A, Rizzo G, et al. Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis. Am J Obstet Gynecol MFM. 2022. PMID: 36402356. doi:10.1016/j.ajogmf.2022.100803

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。